Friday, July 21, 2023
RenovoRx and Imugene have announced a strategic research collaboration aimed at optimising the delivery of Imugene's oncolytic virus therapy using RenovoRx's TAMP (Trans-Arterial Micro-Perfusion) therapy platform.
The collaboration aims to explore the feasibility and benefits of delivering Imugene's CF33 oncolytic virus technology trans-arterially using RenovoRx's TAMP platform. Moreover, this collaboration focus to target difficult-to-access tumours, such as those found in pancreatic and liver cancers.
By combining Imugene's CF33 oncolytic virus technology with RenovoRx's TAMP therapy platform, aim to address the challenges associated with treating tumours in regions that are hard to reach using traditional administration methods. In such difficult-to-access tumours, dense fibrous tissue and limited blood vessel supply have been known to hinder the uptake of therapy.
This joint effort represents a significant milestone to expand the treatment pipeline from solely addressing locally advanced disease to potentially treating metastatic disease with immunotherapy.
By combining RenovoRx's precise drug delivery system with Imugene's CF33 oncolytic virus platform, there is the potential to enhance the treatment of challenging cancers and offer new hope to patients facing difficult-to-treat tumours.
